Advancing Science

in the Pharmaceutical and Biotechnology Sector

Q2 2024

Disclaimer

This presentation has been prepared by DRI Healthcare Trust (the "Trust"). The Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario, Canada and is externally managed by DRI Capital Inc. ("DRI Healthcare"). The Trust completed an initial public offering (the "IPO") on February 11, 2021, in which it acquired an initial portfolio of royalty assets from DRI Healthcare. The predecessor of DRI Healthcare was founded in 1989. Any references to employees or historical figures prior to the IPO refer to those of DRI Healthcare.

Cautionary Note Regarding Forward-Looking Information

This presentation, including responses to questions related thereto, may contain "forward-looking information" within the meaning of, and made pursuant to the "safe harbor" provisions of, Canadian provincial securities laws. Statements that contain forward-looking information are predictive in nature, depend upon or refer to future events or conditions, and include, but are not limited to, statements which reflect management's current opinions, estimates and assumptions regarding the operations, business, investment opportunities, the profitability and availability of royalty investments, results, performance, financial position and compounding of cash flow, expected financial results, priorities, objectives, strategies, prospects, pipeline, capital management and both short- and long-term outlook of the Trust and its subsidiaries, which are based on management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate and reasonable in the circumstances. Statements containing forward-looking information are typically identified by words such as "guidance," "target," "project," "assumes," "seek," "objective," "outlook," "commitment," "believe," "expect," "will," and other similar expressions.

Despite careful consideration and review of the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct, and undue reliance should not be placed on such statements. Forward-looking information is subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results to materially differ from those depicted or implied by such information, including but not limited to the risk factors or assumptions identified in the Trust's most recent Management's Discussion and Analysis ("MD&A"), under "Risk Factors" in the Trust's most recent Annual Information Form, and in the Trust's other filings with Canadian securities regulators available on SEDAR+ at www.sedarplus.ca.

The forward-looking information contained in this presentation represents management's expectations as of the date of this presentation, and are subject to change after such date. Except as may be required by applicable securities laws, the Trust does not undertake any obligation to update or revise any statement containing forward-looking information in this presentation, whether as a result of new information, future events or otherwise.

Non-GAAP Measures and Ratios

This presentation also makes reference to certain non-GAAP financial measures including Total Cash Receipts, Normalized Total Cash Receipts, Total Cash Royalty Receipts and Adjusted EBITDA, and certain non-GAAP ratios including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized measures under the International Financial Reporting Standards ("IFRS") and are therefore unlikely to be comparable to similar financial measures disclosed by other issuers. Rather, these measures and ratios are provided as additional information to complement those IFRS measures by providing further understanding of the Trust's financial performance from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of financial information reported under IFRS. See "Financial Review: Non-GAAP Financial Measures" in the MD&A, which includes a reconciliation of IFRS to non-GAAP measures, such reconciliation being incorporated by reference herein.

All dollar figures in this presentation are stated in US dollars.


Executive Summary DRI Healthcare is a pioneer in pharmaceutical royalty monetization

DRI Healthcare excels at sourcing, analyzing and executing strategic royalty acquisitions of growing assets. We provide capital to parties along the biopharmaceutical value chain to help fund the future of innovation.

We hold a diversified portfolio of interests in drugs that address significant unmet needs, are marketed by leading biotech or pharma companies and are backed by robust intellectual property and regulatory protection.

Pharmaceutical royalty model

DRI Healthcare sources deals from all parties along the drug development value chain



Each constituent sells royalties for different reasons

Inventors

sell royalties for tax planning and philanthropic reasons

Academic institutions

sell royalties to offset budget shortfalls or to fund large capital projects

Drug developers

sell royalties to fund R&D programs or divest a non-core asset

Drug marketers

create synthetic royalties as an alternative form of non-dilutive financing



Our competitive advantages

Seasoned team

Specialized investment professionals with life science backgrounds and advanced business and science degrees 2 Disciplined capital allocation

Robust investment criteria that have resulted in strong returns 3 Proactive sourcing

Proprietary database tracking royalties on more than 2,500 drugs combined with deep industry relationships



Fundamental ground-up diligence on opportunities to execute high-quality transactions

Experienced and engaged team Retaining top-tier talent is key to our long-term success



Ali Hedayat Acting Chief Executive Officer & Board Member

27 years' experience



Navin Jacob Executive Vice President & Chief Investment Officer

24 years' experience



Sandy Kwan Acting Chief Financial Officer

31 years' experience





13 years' experience



Gurminder Chahal Vice President, Human Resources

19 years' experience



Heather Pals General Counsel & Chief Compliance Officer

12 years' experience




David Plow Chief of Staff

21 years' experience

INVESTMENT TEAM



STAFF




GENDER DIVERSITY



6

Diversified, risk-mitigated portfolio

Provides large pharmaceutical company characteristics without traditional pharma risks and costs



1. Excludes \$138 million in potential additional deployment in milestones. 2. Adjusted EBITDA and Adjusted Cash Earnings per Unit are non-GAAP measures and Adjusted EBITDA Margin is a non-GAAP ratio. See "Financial Review: Non-GAAP Financial Measures" in our MD&A.

8

Focused on closing accretive transactions

Completed thirteen transactions since IPO totaling up to \$1.0 billion, with \$894 million deployed to date¹


	INVESTMENT THESIS	TRANSACTION SIZE	
≫ enpozyme [™]	Only approved product for acid sphingomyelinase deficiency ("ASMD") with strong IP protection and long duration	\$30 million\$13.25 million²+ up to \$26.5 million in potential milestones+ up to \$32.5 million in potential milestones	
OMIDRIA [®]	Uncapped transaction on established product providing cash accretion	\$125 million	Up to \$170 million ³
⁰ ORSERDU ¹	Newly approved and first in class oncology product with uncapped growth potential	\$85 million	Up to \$140 million ⁴
Solo vonjo	High-quality oncology product with strong growth potential	Up to \$135 million ⁵	\$66 million ⁶
Tzield	Newly approved Diabetes product with long-term cash flows and growth potential	Acquisition: \$100 million Sale: \$210 million	
Zejula	High-quality oncology product with multiple pipeline indications	\$35 million + \$10 million potential milestone	
SEMPAVELI SYFOVRE	Hematology and ophthalmology products with long-term horizon and attractive growth prospects	\$28.2 million ⁷ + \$4 million potential milestone	
Oracea	Dermatology product with existing commercial track record	\$50.5 million	

Excludes \$138 million in additional milestone obligations.
 Represents a second royalty on Xenpozyme acquired from HLS Therapeutics Inc.
 Represents the expansion of the royalty entitlement on the US net sales of Omidria from Omeros Corp.
 Represents a second royalty on Orserdu acquired from Radius Health, Inc.
 Includes \$50 million secured loan made to CTI BioPharma ("CTI"), \$60 million royalty acquired from CTI and \$6.5 million milestone payment made to CTI. The conditions required for the second milestone payment of \$18.5 million were not met by the end of the third quarter of 2023 and the additional milestone payment was not made. CTI repaid its loan in full and the related credit agreement was terminated.
 Represents a second royalty on Vonjo acquired from S*Bio Pte Ltd.
 Includes \$24.5 million royalty acquired from a separate counterparty.

Attractive Market

Long-term drivers support royalty financing growth


Growing capital needs to develop novel drugs bolsters our pipeline



1. The five-year forward pipeline value is defined as the projected pipeline value five years in the future; for example, \$263 billion is the projected 2028 revenue from all pipeline products as of 2023. Source: Boston Consulting Group, New Drug Modalities 2023, June 2023. 2. Source: Evaluate Pharma World Preview 2023: Pharma's Age of Uncertainty, August 2023. 3. Source: IQVIA Global Use of Medicines 2024, Outlook to 2028, January 2024.

Current state of the biotech market

Lack of equity market funding makes the Trust's royalty financing very attractive



Rapid expansion of biotech market with >500 IPOs in last 10 years


Struggling equity capital markets for biotechs


1. Source: Jefferies Biotechnology IPO Screens, July 2024. 2. Source: TSX InfoSuite as of August 1, 2024. See "Appendix B – Industry Metrics and Ratios" at the end of this presentation.

Biotechs' limited cash reserves highlight opportunities for royalty financing¹

65% of unprofitable NASDAQ-listed biotechs are estimated to have <2 years of cash







Strong Execution



Q2 2024 financial highlights

Normalized Total Cash Receipts¹ \$43.0 million

1 50% over Q2 2023

Total Income \$41.6 million

12 48% over Q2 2023

Adjusted EBITDA¹ \$32.9 million

11% over Q2 2023

Adjusted EBITDA Margin¹

77%

Adjusted Cash Earnings per Unit¹ \$0.49


Declared Cash Distributions per Unit

\$0.085

Robust diversified portfolio

Portfolio currently consists of 26 royalty streams on 19 products

No individual product accounts for more than 27% of net book value¹



Portfolio performance Portfolio assets show continued growth into 2024

Total Cash Royalty Receipts¹ Net Book Value LTM 06/30/2024 06/30/2024 (\$ millions) THERAPEUTIC AREA Xenpozyme[™] Lysosomal Storage Disorder 1.3 41.2 OMIDRIA* Ophthalmology 26.3 205.2 ⁰ORSERDU Oncology 67.1 195.2 SON NON S Hematology 18.8 114.9 Zejula Oncology 3.5 28.9 GEMPAVELI SYFOVRE Hematology / Ophthalmology 4.0 23.4 9.4 17.5 Oracea Dermatology **EYLEA** Ophthalmology 6.7 14.4 FluMist.Quadrivalent Influenza 0.9 **Matpara** Endocrinology 2.5 1.6 RYDAPT Oncology 7.6 6.2 Neurology 15.9 71.3) Stelara' Simponi' | L (R | S' Immunology 0.9 1.0 Xolair Immunology 10.0 39.5 C Zytiga Oncology 7.2 12.6 Other Products² Various 1.7 1.7 \$184.0 \$774.8 TOTAL

1. Total Cash Royalty Receipts is a non-GAAP measure. See "Financial Review: Non-GAAP Financial Measures" in our MD&A. 2. Includes royalty assets which are not individually material, as well as royalty assets which are fully amortized or, where applicable, the entitlements to which have substantially expired.

Xenpozyme II royalty transaction

Second royalty on long-term asset further increases portfolio duration

TRANSACTION OVERVIEW

Xenpozyme[™]

Approved by the EMA in June 2022 and by the FDA in August 2022 for the treatment of ASMD

\$13.25 million up front purchase price

Approximately 1% royalty on worldwide sales

Entitled to receive all royalties up to \$6.3 million in royalty receipts per calendar year, with an economic sharing agreement for all royalty receipts above this amount

Royalties collected semi-annually

Deal completed in June 2024

STRONG GROWTH POTENTIAL

\$32.5 million in potential milestone payments based on Xenpozyme achieving certain annual net sales thresholds

First and only approved product for the treatment of ASMD, also known as Neimann-Pick disease

Royalties are expected to expire in Q2 2036

Omidria expansion transaction

Highly accretive transaction with both near and long-term cash flow generation



TRANSACTION OVERVIEW

Approved by FDA in May 2014 and by the EMA in July 2015 for intracameral use during cataract surgery or intraocular lens replacement to maintain pupil dilation and reduce postoperative pain

\$115 million up front purchase price plus up to \$55 million in potential milestones

30% royalty rate on US net sales through December 31, 2031

Deal completed in February 2024

STRONG GROWTH POTENTIAL

Replaces annual structured caps from original Omidria transaction, giving upside exposure to sales growth

Mature product brings stable sales history and predictable growth

Anticipated significant contribution to cash flows from 2024 through 2031

Material cash flows anticipated to exceed original Omidria transaction's annual caps of \$13 – \$27.5 million



Orserdu royalty transactions

Uncapped royalties on long-duration asset



TRANSACTION OVERVIEW

Orserdu I \$85 million upfront purchase price

Mid-single digit tiered royalty on worldwide net sales

Deal completed in June 2023

Orserdu II

\$130 million upfront plus potential\$10 million milestone payment

Low to high single digit tiered royalty on worldwide net sales

Deal completed in August 2023

Royalties collected on a one-quarter lag

STRONG GROWTH POTENTIAL

Approved by the FDA in January 2023 and the EMA in September 2023 for advanced/metastatic breast cancer patients with ESR1 mutations


Significant progression free survival benefit over standard of care with limited side effects and convenience of oral administration

Trust is entitled to receive regulatory and sales-based incoming milestone payments in addition to royalties

Strong cash generation

Cash available to drive portfolio growth and maintain distributions to unitholders

Adjusted EBITDA for the Last Twelve Months Ended June 30, 2024 (\$M)¹



Adjusted EBITDA Margin¹ 85%

Adjusted Cash Earnings per Unit⁴


\$2.47

Adjusted EBITDA and Normalized Total Cash Receipts are non-GAAP financial measures. Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit are non-GAAP ratios. Adjusted EBITDA Margin is calculated as Adjusted EBITDA / Normalized Total Cash Receipts.
 The Net Change in Royalties Receivable and Interest Receivable represents royalties and interest receivable at the beginning of period, less royalties and interest receivable at the end of period, plus acquired royalties receivable included in the purchase price of the assets, less other interest income and less prepayment premium income on loan receivable.
 Operating expenses are net of \$1.0 million related to board of trustee unit-based compensation.
 Adjusted Cash Earnings per Unit is calculated as comprehensive earnings (loss), plus: (i) amortization of royalty assets, (ii) amortization of other current assets, (iii) impairment of royalty assets, (iv) unit-based compensation, (v) board of trustees unit-based compensation, (vi) management and performance fees on sale of royalty asset and (vii) other loss, less: (i) non-cash interest and other income on loan receivable, (iii) prepayment premium income on loan receivable, (iv) net gain on sale of royalty assets, (v) net gain on derivative instruments; divided by weighted average units outstanding.

Positioned for Growth

Current deployment exceeds targets

5-year deployment target increased to over \$1.25 billion



1. Includes \$24.5 million royalty acquired on July 20, 2022 and \$3.7 million royalty acquired from a separate counterparty on April 3, 2023. 2. We sold our interest in Tzield on April 27, 2023 to an affiliate of Sanofi SA ("Sanofi"). 3. Deployment target is consistent with historical deployment since IPO, combined with assumed future capital availability based on forecasted royalty receipts and credit capacity. Forecasted royalty receipts take into account the existing assets in our portfolio and future execution of transactions in our pipeline of opportunities at a pace consistent with our past performance.

Delivering on our long-term objectives


Focus on sustainable strategic growth

	GUIDANCE AT IPO (FEB 2021)	GUIDANCE TODAY
Capital deployment target	\$650 – \$750 million over 5 years	More than \$1.25 billion over 5 years ¹
Sustainable cash generation	Declining cash curve due to expected asset expiries	High-teens royalty income CAGR through 2025 and mid- to high-single digit royalty income CAGR through 2030 (excluding any new transactions)
Portfolio duration	8 years	>10 years
Capital resources	IPO proceeds and debt capacity	Equity offering proceeds and attractive credit facilities with compounding effect of cash flows

1. Statements regarding the Trust's outlook over 5 years are based on its most up-to-date view of its prospects as of the date of this presentation. This long-term outlook includes potential royalty transactions currently in the Trust's pipeline and future royalty transactions that it may bring into its pipeline in accordance with its strict investment criteria. This long-term outlook assumes no material adverse events following the date of this presentation.

Proactive sourcing provides competitive advantage

Our strong relationships and proprietary processes generate exclusive deal flow



24

Rigorous due diligence process

 Appointment of internal multi-disciplinary deal team Individualized diligence plan and deal size considerations Proactive assessment of deal risks Strategic engagement of external consultants 			
SciMed Review	IP and LOE	Commercial Assessment	Legal
MoA and preclinical review	Comprehensive internal IP assessment of	 Primary and secondary market research 	 Customized deal structure by experienced legal team
 Review of key clinical trials In-depth clinical and patient data analysis 	 patent coverage validity and enforceability	 Detailed market models and third-party forecasts 	Underlying agreement review, including licensing
 Probability of success determination 	freedom to operateLOE	 Competitive landscape evaluation, including product cost comparisons 	 agreements Bankruptcy and overall risk assessment
 Regulatory environment analysis 	litigation risk	Commercial bankruptcy risk	Tax implications
 Targeted KOL research and interviews 	 Specialized IP review and opinions provided by external counsel 	 Marketer assessment and strategy review 	 Legal opinions and additional risk analysis by external
		Deimbursement analysis	counsel

• Reimbursement analysis

Glossary

IP – intellectual property. **KOL** – key opinion leaders. **LOE** – loss of exclusivity. **MoA** – mechanism of action.

DRIHEALTHCARE Robust pipeline of over \$3.2 billion

in potential opportunities¹



Address important unmet needs with life-changing therapies for patients




Marketed by leading biotech or biopharma companies



Provides strong intellectual property and regulatory protection

Compounding cash flows increase growth potential

Enables future acquisitions and delivers value for unitholders



1. The above chart is for illustrative purposes only to depict the effect of reinvesting cash flow over time. The chart was generated using a typical deal cash flow profile based on a historical analysis of DRI Healthcare's internal database of royalty transactions. Key assumptions include original transaction funded with a mix of debt and equity, with interest rate expense, management fees, and other operating costs factored in. **2.** Total Cash Receipts and Adjusted EBITDA are non-GAAP measures. See "Financial Review: Non-GAAP Financial Measures" in our MD&A.

Growth opportunities from existing assets¹

Additional indications have potential to enhance royalty streams

	PHASE 1	PHASE 2	PHASE 3	PHASE 4
	RESPOND: Spinraza in patients who had received	Zolgensma		
Spinraza	ASCEND: Higher dose Spinraza in patients who ha	d received Evrysdi		
	DEVOTE: Higher dose Spinraza			
Vonjo	PACIFICA: Confirmatory trial in Myelofibrosis			
	FIRST: 1L treatment of stage III/IV Ovarian Cancer	with Dostarlimab		
Zejula	ZEAL: 1L maintenance therapy in combination wit	h pembrolizumab in NSCLC		
	AMPLITUDE: Combination of Zytiga + Zejula in mH	SPC		
Zytiga	MAGNITUDE: Combination of Zytiga + Zejula in m	CRPC		
	AMPLITUDE: Combination of Zytiga + Zejula in mH	SPC		
Empaveli /	VALIANT: Treatment for C3G and IC-MPGN			
Syfovre	PLAUDIT: Treatment for wAIHA or CAD			
Orserdu	ELEVATE: Combination therapy for ER+/HER2- mB	c		
	ELECTRA: Combination therapy for ER+/HER2- mB	c		
	ELCIN: Monotherapy in CDK4/6 inhibitor naïve ER-	-/HER2- mBC		
	SUMIT-ELA: Combination therapy for ER+/HER2- n	nBC		
Rydapt	Rydapt + decitabine in unfit AML patients			

1. Growth opportunities represent ongoing trials for some of the products in our portfolio to be used in additional indications. We do not make any representations that such trials will be ultimately successful, or regarding the Trust's performance if such trials were to be successful.

Committed to ESG practices

Striving to deliver value to our stakeholders, our community, and society as a whole



Environmental

Building a platform for sustainability

- Review of our partners' sustainability practices
- Head office located in a Gold LEEDcertified building
- Committed to waste reduction
- Employee environmental training and awareness



Social

Valuing diversity and community support

- Highly diverse and inclusive team
- Balanced gender representation
- Employee paid time off for charitable volunteering
- Professional development and career advancement
- Corporate giving and donations



Governance

Accountability and integrity as core values

- Strong governance practices and policies
- Diverse and majority independent Board
- Board oversight of ESG and risk management
- Active unitholder engagement
- Robust cybersecurity
- Whistleblower policy

_{Key} priorities



Rebuild the trust and the confidence of our unitholders



Invest in our people and build the industry leading royalty investment team



Execute on strong pipeline and operate at peak performance



Focus on long-term, sustainable growth generating strong unitholder returns

Trust units are undervalued relative to royalty peers

Valuation comparisons highlight Trust's underlying value¹

	PRICE / BOOK	PRICE / OPERATING CASH FLOW ²	DIVIDEND YIELD
DRIHEALTHCARE	0.9x	2.8x	7.6%
ROYALTY PHARMA	2.0x	6.4x	2.9%
XOMA	3.8x	Neg	0.0%
Ligand	2.4x	57.5x	0.0%
Franco-Nevada	4.3x	25.8x	1.0%
VIENTICALS WETALS	3.8x	32.5x	1.0%

1. Information sourced from the Trust's Q2 2024 financial statements and all other companies' Q1 2024 financial statements and share price as of July 31, 2024. 2. Trust cash flow calculated as Cash Flow from Operating Activities plus Cash Interest Received less Cash Interest Paid.

DRIHEALTHCARE Investment Highlights



Founded in 1989, DRI Healthcare is the pioneer and a global **leader** in healthcare royalty investing



DRI Healthcare believes it is well positioned to capitalize on generational industry growth delivering attractive **uncorrelated cash flows**



Diversified portfolio of products by therapeutic area and marketer



Potential for high margin value opportunity on self-liquidating **asset** class generating quarterly cash flows




Decades-long industry relationships and highly specialized investment capabilities create strong barriers to entry

Contact us David Levine

🞽 ir@drihealthcare.com

Appendix A Deal Summaries



Vonjo II royalty transaction

Second royalty on Vonjo increases exposure to long duration high-quality asset



TRANSACTION OVERVIEW

Approved by the FDA in February 2022 as the only treatment for myelofibrosis with severe thrombocytopenia

\$66 million purchase price for a tiered royalty on worldwide net sales

Trust is entitled to receive up to \$107.5 million in incoming milestone payments

Deal completed in July 2023

STRONG GROWTH POTENTIAL

First year of sales strongly exceeded analyst consensus estimates

\$6.5 million payment made to CTI in January 2023 for achieving sales milestone on Vonjo I royalty

In June 2023, Sobi acquired CTI for \$1.7 billion

Tzield royalty transaction

Proceeds reinvested to generate compound effects for unitholders



ACQUISITION FROM MACROGENICS

Approved by the FDA in November 2022 for the treatment of stage 2 Type 1 diabetes

\$100 million up front purchase price for a single digit royalty on worldwide net sales

Up to a \$50 million potential milestone tied to the successful advancement of treatment of newly diagnosed or recent-onset Type 1 diabetes by 2028

Additional \$50 million potential milestone payment based on exceeding certain sales thresholds

Deal completed in March 2023

SALE TO SANOFI

Sanofi announced agreement to acquire Provention Bio days after the Trust's acquisition of the royalty

\$210 million upfront sale for the Trust's royalty entitlement

Sanofi is now obligated to pay the two \$50 million milestones to Macrogenics if they are achieved

Deal completed in April 2023

Xenpozyme I royalty transaction

Xenpozyme[™]

Long duration product with strong IP protection anticipated to generate high multiple on invested capital

Approved by the EMA in June 2022 and by the FDA in August 2022 for the treatment of ASMD

\$30 million up front purchase price

Approximately 1% royalty on worldwide sales

TRANSACTION OVERVIEW

Royalties collected semi-annually

Deal completed in November 2022

STRONG GROWTH POTENTIAL

\$26.5 million in potential milestone payments based on cumulative royalties received

First and only approved product for the treatment of ASMD, also known as Niemann-Pick disease

Royalties are expected to expire in Q4 2036

Omidria I royalty transaction¹

Substantial near-term cash flows with long-term structural growth anticipated



TRANSACTION OVERVIEW

Approved by the FDA in May 2014 and by the EMA is July 2015 for intracameral use during cataract surgery or intraocular lens replacement


\$125 million up front purchase price, subject to annual cash receipt caps

Marketed by Rayner Surgical with royalties collected monthly

Deal completed in October 2022

STRUCTURED GROWTH

Annual Royalty Receipt Caps (\$M)



Zejula royalty transaction

Multiple indications in development represent a pipeline in a product



TRANSACTION OVERVIEW

Approved by the FDA in March 2017 and by the EMA in November 2017 for the treatment of ovarian cancer

\$35 million up front purchase price

0.5% net royalty on worldwide net sales by GSK

Royalties collected on one-quarter lag

Deal completed in September 2022

STRONG GROWTH POTENTIAL

\$10 million milestone payment if Zejula is approved by FDA for the treatment of endometrial cancer by December 31, 2025

In development for metastatic castrate sensitive and resistant prostate cancer, endometrial cancer, HER2-breast cancer, and non-small cell lung cancer

Royalties are expected to expire in Q2 2033

Empaveli royalty transaction Long-term horizon and attractive growth prospects

TRANSACTION OVERVIEW

SYFOVR

Empaveli: Approved by the FDA in May 2021 and by the EMA in December 2021 for the treatment of Paroxysmal Nocturnal Hemoglobinuria ("PNH")

Syfovre: Approved by the FDA as the first and only treatment for Geographic Atrophy in February 2023

\$28.2 million purchase price¹ plus a\$4.0 million potential milestone payment

<1% royalty on worldwide net sales up to \$500 million per annum

Deal completed in July 2022

STRONG GROWTH POTENTIAL

Represents a significant advancement in the standard of care for PNH

In development for pipeline indications including Cold Agglutinin Disease and C3 Glomerulopathy

Option to increase the annual sales cap to \$1.1 billion in return for a one-time payment of \$21 million²



Oracea royalty transaction Strong cash flows generate immediate revenues



TRANSACTION OVERVIEW

Approved by the FDA in 2006 for the treatment of Papulopustular Rosacea

\$50.5 million purchase price for royalties on worldwide sales

Deal completed in September 2021

STRONG GROWTH POTENTIAL

It has an established commercial track record and brings immediate accretive value with substantial royalty receipts netted out of purchase price

Among leading treatment options for managing papulopustular rosacea

Two additional royalty interests acquired as part of transaction


Royalties collected on a one-quarter lag and are expected to expire in Q1 2028

Deal structure case study: CTI BioPharma / Vonjo

Proven ability to provide flexibility in deal structuring while managing risk

	CTĨ		
Pre-approval	\$50 million secured loan	€	 Funding for Vonjo launch preparation Secured loan provided downside protection if approval not granted
Upon approval	\$60 million tiered royalty	Ð	 Funding for Vonjo launch Sliding royalty rates as annual sales increase DRI Healthcare obtains higher royalty on lower tranche of annual sales
Milestones by Q3 2023	Up to \$25 million ¹	⇒	 Two potential milestones in event Vonjo sales exceeded certain thresholds by Q3 2023 Risk sharing for different launch curves

Appendix B Industry Metrics



Industry Metrics

References in this presentation to a securities index or other benchmark are made for informational purposes only and an investment in the Trust is unlike an investment in an index of securities or the aggregate funds constituting such benchmark. The investment characteristics of such index or benchmarks may differ materially from the Trust, and an investment in the Trust is not comparable to an investment in such an index (or benchmark) or in the securities that comprise the index (or benchmark). The risk/return profile in the index or benchmark is also typically materially different from that of the Trust. The Trust does not trade in any of the securities represented in the index, and the Trust may employ leverage, hedging, and other investment strategies that may not be incorporated in the index. In addition, investing in the Trust is generally subject to expenses, management fees, and performance fees or allocations payable by the Trust, none of which are reflected in the index. Further, the index or benchmark is not necessarily used or selected by the Trust as an appropriate benchmark to compare relative to the performance of the Trust, but rather it is included because the Trust believes it serves as a useful point of comparison and is a well known and widely recognized index or benchmark. The Trust is not managed to track the performance of the index referenced herein.

The **S&P 500 Total Return Index** is calculated based on price changes and reinvested dividends of the S&P 500® index, which includes 500 companies in leading industries of the U.S. economy, capturing 75% coverage of U.S. equities. The index is composed almost entirely of common stocks of companies listed on the New York Stock Exchange (including NYSE Arca and NYSE Amex) and NASDAQ stock market. REITs (excluding mortgage REITs) and business development companies are also eligible for inclusion. Additions to the index must have over \$4 billion in market capitalization, a public float of at least 50%, four consecutive quarters of positive as-reported earnings, adequate liquidity and reasonable price. The S&P 500 Index is an unmanaged, market-value weighted index with each stock's weight in the index proportionate to its market value.

The **BTK Price Index** represents common stocks or American depository receipts of selected companies involved in the biotechnology industry, and listed on the NYSE, NASDAQ, NYSE MKT, or another major U.S. exchange.

The **S&P Biotechnology Select Industry**® represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted.

The **SPX Index** is Standard and Poor's 500, or commonly known as the S&P 500, is an index that includes 500 leading companies and covers approximately 80% of available market capitalization.